Clinical Trials
7 trialsNCT01827111 2022-02-08
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04979585 2021-08-03
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
The First Hospital of Jilin University
Phase 2 Unknown
NCT02158520 2020-01-21
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Completed
NCT02300935 2019-05-30
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
SCRI Development Innovations, LLC
Phase 1 Withdrawn
NCT02065466 2016-04-21
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
University of Arizona
Phase 1/2 Withdrawn
NCT00833807 2015-11-26
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00970996 2013-01-03
BCAA
M.D. Anderson Cancer Center
Phase 1 Completed